Empagliflozin reduces hospitalisation risk for heart-failure and cardiovascular death by 21 per cent, shows Boehringer Ingelheim’s Emperor-Preserved trial Read more
US FDA approves Jardiance to treat adults living with heart failure with reduced ejection fraction Read more
Pharma industry’s digital maturity has accelerated with the adoption of digital engagement channels Read more
Lupin announces achievement of key milestones for its clinical stage MEK inhibitor compound Read more
Boehringer Ingelheim India to sustain growth momentum in 2021, focuses on partnerships in NCD management Read more